AIMT - Aimmune Suffers Delay But Not Of Its Own Making
Aimmune (AIMT) suffered a setback and through no fault of its own. It was notified by the FDA that its Biologics Licensing Application ((BLA)) would not be reviewed because of the government shutdown. The stock fell about 5% on Monday after the release of the news, and then slightly again on Tuesday of this week. However, I believe that it's still a good biotech to look into. It has the ability to eventually gain FDA approval of its drug based on its safety and efficacy.
Regulatory Setback
The FDA notified Aimmune that due